Double Bond Pharmaceutical's second patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in the United States. Patent approval provides protection for the treatment method and the design of composition for DBP's front-line product SA-033.
"We are very pleased because it is an important milestone in the development of balanced product pipeline", - comments Igor Lokot, CEO of DBP.
More about SA-033: SA-033 is the first drug candidate that DBP has developed using its innovative drug delivery technology BeloGal®. Due to innovative formulation controls targeting of doxorubicin to the liver, the concentration of the active substance in the desired target organ increases, which enhances efficacy and reduces the toxic side effects that are common in systemic chemotherapy.
More about BeloGal®: BeloGal® is DBP’s innovative drug-delivery platform which targets pharmaceutically active compounds to lung or liver. Video presentation: https://youtu.be/2PKi51PW75Q 

This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-06-2021 08:30 CET.

____________________________________________________________________
Fullständigt bolagsnamn:     Double Bond Pharmaceutical International AB (publ)
Organisationsnummer:        556991-6082
Aktiens kortnamn:               DBP B
Aktiens ISIN-kod:               SE0007185525 
För mer information, kontakta: 
Igor Lokot, VD
Hemsida: http://www.doublebp.com/
Maila till: info@doublebp.com
Följ oss på LinkedIn och Twitter!
____________________________________________________________________
Information om Double Bond Pharmaceutical International AB
DBP är ett farmaceutiskt bolag med verksamhet som inriktar sig framför allt på behandling av cancersjukdomar genom en egenutvecklad drug-delivery-teknologi. Bolaget har i juni 2015 beviljats Orphan Drug Designation-status av European Medicines Agency (EMA) för sin första produkt, SA-033, för behandling av hepatoblastom. Double Bond Pharmaceutical har i oktober 2015 förvärvat rättigheterna till Temodex – ett läkemedel registrerat i Vitryssland för behandling av hjärntumörer. Bolaget har i juli 2016 beviljats Orphan Drug Designation-status av EMA för Temodex.